Farallon Capital Management’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $669M | Buy |
6,348,906
+204,900
| +3% | +$18.1M | 3.81% | 8 |
|
|
2025
Q4 | $537M | Sell |
6,144,006
-52,000
| -0.8% | -$4.26M | 2.43% | 13 |
|
|
2025
Q3 | $412M | Buy |
6,196,006
+24,000
| +0.4% | +$1.36M | 1.68% | 20 |
|
|
2025
Q2 | $341M | Buy |
6,172,006
+65,000
| +1% | +$3.12M | 1.43% | 28 |
|
|
2025
Q1 | $295M | Buy |
6,107,006
+177,000
| +3% | +$7.42M | 1.42% | 29 |
|
|
2024
Q4 | $229M | Buy |
5,930,006
+69,000
| +1% | +$3.01M | 1% | 36 |
|
|
2024
Q3 | $264M | Buy |
5,861,006
+20,233
| +0.3% | +$817K | 1.16% | 31 |
|
|
2024
Q2 | $202M | Buy |
5,840,773
+101,800
| +2% | +$2.98M | 0.87% | 34 |
|
|
2024
Q1 | $166M | Buy |
5,738,973
+4,543
| +0.1% | +$124K | 0.7% | 36 |
|
|
2023
Q4 | $131M | Buy |
5,734,430
+288,000
| +5% | +$5.04M | 0.6% | 39 |
|
|
2023
Q3 | $90.8M | Buy |
5,446,430
+935,000
| +21% | +$18.1M | 0.42% | 44 |
|
|
2023
Q2 | $125M | Buy |
4,511,430
+1,896,416
| +73% | +$47.5M | 0.63% | 41 |
|
|
2023
Q1 | $60.1M | Sell |
2,615,014
-1,036,873
| -28% | -$17.4M | 0.33% | 57 |
|
|
2022
Q4 | $39.8M | Hold |
3,651,887
| – | – | 0.24% | 67 |
|
|
2022
Q3 | $30.8M | Sell |
3,651,887
-48,721
| -1% | -$461K | 0.17% | 86 |
|
|
2022
Q2 | $29.3M | Buy |
3,700,608
+2,566,151
| +226% | +$31M | 0.16% | 85 |
|
|
2022
Q1 | $26.9M | Sell |
1,134,457
-782,677
| -41% | -$22.1M | 0.13% | 86 |
|
|
2021
Q4 | $65.6M | Sell |
1,917,134
-474,866
| -20% | -$15M | 0.33% | 58 |
|
|
2021
Q3 | $42.4M | Buy |
2,392,000
+62,320
| +3% | +$2.66M | 0.2% | 79 |
|
|
2021
Q2 | $105M | Sell |
2,329,680
-95,320
| -4% | -$3.15M | 0.43% | 52 |
|
|
2021
Q1 | $62.8M | Hold |
2,425,000
| – | – | 0.31% | 63 |
|
|
2020
Q4 | $48.9M | Sell |
2,425,000
-325,000
| -12% | -$6.99M | 0.29% | 64 |
|
|
2020
Q3 | $53.8M | Buy |
2,750,000
+250,000
| +10% | +$4.69M | 0.37% | 62 |
|
|
2020
Q2 | $44.1M | Buy |
2,500,000
+1,000,000
| +67% | +$12.5M | 0.35% | 59 |
|
|
2020
Q1 | $10.6M | Hold |
1,500,000
| – | – | 0.09% | 79 |
|
|
2019
Q4 | $10.6M | Hold |
1,500,000
| – | – | 0.07% | 99 |
|
|
2019
Q3 | $18M | Hold |
1,500,000
| – | – | 0.14% | 76 |
|
|
2019
Q2 | $18.2M | Sell |
1,500,000
-290,000
| -16% | -$3.21M | 0.12% | 80 |
|
|
2019
Q1 | $22.5M | Sell |
1,790,000
-409,674
| -19% | -$3.62M | 0.17% | 70 |
|
|
2018
Q4 | $14.8M | Sell |
2,199,674
-43,528
| -2% | -$345K | 0.11% | 74 |
|
|
2018
Q3 | $23.1M | Buy |
2,243,202
+1,332,973
| +146% | +$11.5M | 0.14% | 62 |
|
|
2018
Q2 | $6.12M | Sell |
910,229
-103,271
| -10% | -$793K | 0.04% | 84 |
|
|
2018
Q1 | $8.71M | Buy |
1,013,500
+113,500
| +13% | +$2.14M | 0.06% | 77 |
|
|
2017
Q4 | $18.7M | Buy |
+900,000
| New | +$16M | 0.15% | 58 |
|
Other funds holding PTGX
RI
VPM
VCM
JJ
Farallon Capital Management's PTGX Position: Q1 2026 in Review
Farallon Capital Management increased its Protagonist Therapeutics (PTGX) stake by 3.3% in Q1 2026, buying an estimated $18.1M and bringing the position to 6,348,906 shares worth $669M. The position accounts for 3.81% of the portfolio, ranked #8.
Farallon Capital Management first reported a position in PTGX in Q4 2017 and has held it in 34 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.
- Farallon Capital Management held 6,348,906 shares of Protagonist Therapeutics worth $669M as of Q1 2026.
- Farallon Capital Management bought 204,900 Protagonist Therapeutics shares in Q1 2026, an estimated $18.1M.
- Protagonist Therapeutics made up 3.81% of Farallon Capital Management's portfolio in Q1 2026, its #8 holding.
- Farallon Capital Management first reported a position in Protagonist Therapeutics in Q4 2017 and has held it in 34 quarters since.
- 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.
Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.